Insider Selling: Arvinas (NASDAQ:ARVN) CFO Sells $61,043.26 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik sold 5,134 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $11.89, for a total value of $61,043.26. Following the sale, the chief financial officer owned 159,267 shares of the company’s stock, valued at $1,893,684.63. This trade represents a 3.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Arvinas Stock Performance

Shares of ARVN opened at $11.99 on Friday. The stock has a market capitalization of $770.00 million, a P/E ratio of -14.80 and a beta of 1.88. Arvinas, Inc. has a 1 year low of $5.90 and a 1 year high of $19.05. The company’s fifty day moving average is $12.36 and its two-hundred day moving average is $10.38.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ARVN. Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Wedbush reaffirmed a “neutral” rating and set a $9.00 price target on shares of Arvinas in a research note on Thursday, November 6th. Wells Fargo & Company decreased their price objective on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Finally, Citigroup raised shares of Arvinas from a “neutral” rating to a “buy” rating and increased their target price for the company from $10.00 to $15.00 in a report on Tuesday, January 6th. Ten analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $13.12.

Institutional Investors Weigh In On Arvinas

A number of large investors have recently bought and sold shares of ARVN. Monaco Asset Management SAM boosted its stake in shares of Arvinas by 185.6% during the second quarter. Monaco Asset Management SAM now owns 900,936 shares of the company’s stock valued at $6,631,000 after acquiring an additional 585,477 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Arvinas by 791.1% during the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock worth $10,498,000 after buying an additional 1,267,593 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its position in shares of Arvinas by 307.7% in the third quarter. Campbell & CO Investment Adviser LLC now owns 223,576 shares of the company’s stock valued at $1,905,000 after buying an additional 168,744 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Arvinas by 28.7% during the third quarter. Nordea Investment Management AB now owns 557,742 shares of the company’s stock valued at $4,730,000 after buying an additional 124,254 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Arvinas in the 2nd quarter worth approximately $390,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.